Erika Handly, Brigham Young University
Engineering
The development of an effective treatment for cancer is one of the most important goals for research today. One method of treatment is a targeted delivery mechanism using encapsulating drug carriers paired with a release mechanism. The Pitt laboratory has developed a potent chemotherapeutic called eLipoDox that uses a liposomal delivery construct combined with ultrasound release. eLipodox is composed of a liposome that encases an emulsion and the drug Doxorubicin. The emulsion droplet is a perflourocarbon stabilized by a lipid bilayer that contains a high vapor pressure solvent that will expand and burst the liposome upon sonication. The liposome is an artificially made lipid bilayer membrane that effectively encases the drug and does not allow the drug to diffuse freely through the body. Doxorubicin works through intercalating DNA, or distorting the structure of DNA, which is effective in treating tumors. However, it can cause heart failure and thus can have deathly effects for human patients. Encapsulating Doxorubicin minimizes the effects of Doxorubicin to other parts of the body while increasing the efficiency of the drug. Currently, the efficiency of loading the chemotherapeutic drug into the liposome is only around 34 to 38 percent, which is not ideal due to how expensive the drug is and the labor required to make the carrier. Thus, the purpose of this research was to systematically examine loading parameters and test the optimized carrier on a human cancer cell line. Higher temperature, greater sonication rounds, and lower concentration of drug on the exterior all correlated to greater loading efficiency. Cell death was also demonstrated with the optimized construct.